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Novel iodinated tracers, MIBG and BMIPP,
for nuclear cardiology
Nagara Tamaki, MD, PhD,
a and Keiichiro Yoshinaga, MD, PhD, FACC
b
With the rapid growth of molecular biology, in vivo imaging of such molecular process (i.e.,
molecular imaging) has been well developed. The molecular imaging has been focused on
justifying advanced treatments and for assessing the treatment effects. Most of molecular
imaging has been developed using PET camera and suitable PET radiopharmaceuticals.
However, this technique cannot be widely available and we need alternative approach.
123I-
labeled compounds have been also suitable for molecular imaging using single-photon com-
puted tomography (SPECT)
123I-labeled meta-iodobenzylguanidine (MIBG) has been used for
assessing severity of heart failure and prognosis. In addition, it has a potential role to predict
fatal arrhythmia, particularly for those who had and are planned to receive implantable car-
dioverter-deﬁbrillator treatment.
123I-beta-methyl-iodophenylpentadecanoic acid (BMIPP)
plays an important role for identifying ischemia at rest, based on the unique capability to
represent persistent metabolic alteration after recovery of ischemia, so called ischemic memory.
Since BMIPP abnormalities may represent severe ischemia or jeopardized myocardium, it may
permit risk analysis in CAD patients, particularly for those with chronic kidney disease and/or
hemodialysis patients. This review will discuss about recent development of these important
iodinated compounds.
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INTRODUCTION
Molecular cardiovascular imaging has an important
role for imaging cardiovascular disorders in molecular
and cellular levels in vivo. This technique has a potential
to assess severity of myocardial disorders such as heart
failure (HF), severe coronary artery disease (CAD), and
various types of cardiomyopathy. Molecular imaging
has possibilities in monitoring treatments, and prediction
of suitable treatment. Thus, molecular imaging is
expected for clinical use for making treatment strategy
in various cardiovascular disorders.
1
Cardiac PET is a powerful, quantitative imaging
modality which has been most extensively used to
investigate cardiaovascular biology and physiology.
2,3
On the other hand, various
123I-labeled compounds have
been introduced for molecular imaging in most of clin-
ical centers using conventional gamma cameras without
need of cyclotron. Longer half life of
123I (13 hours) is
suitable for delivering long distance from
123I supply
centers. Japan has extensive clinical experiences with
two major iodinated compounds:
123I-meta-iodobenzyl-
guanidine (MIBG) and
123I-15-(p-iodophenyl)-3R,S-
methyl pentadecanoic acid (BMIPP). This article will
review the clinical values of these novel tracers,
including most recent topics, such as predicting fatal
arrhythmias by MIBG and silent ischemia in chronic
kidney disease (CKD) by BMIPP.
MIBG IMAGING
MIBG, a presynaptic imaging agent, is norepi-
nephrine analog which is concentrated and stored in the
myocardium in a similar fashion as norepinephrine.
4 Its
uptake is primarily through the energy requiring, high
afﬁnity, low capacity, ‘‘uptake 1’’ norepinephrine
transporter mechanism.
5,6 MIBG is washed out from the
myocardium, but in contrast to norepinephrine, it is not
catabolized by monamine oxidase or catechol-O-methyl
transferase (COMT). Thus, the assessment of MIBG
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135uptake and washout allows the unique characterization
of sympathetic aspect of autonomic cardiac function.
Patients are usually instructed overnight fast prior to
MIBG studies. Following intravenous administration of
111-370 MBq (3-10 mCi) of MIBG, anterior planar
imaging and single-photon computed tomography
(SPECT) are acquired at 30 minutes (early phase) and 4
hours (delayed phase). In order to minimize scatter noise
from high-energy photons from
123I, medium-energy
collimators or
123I collimators are preferred to the con-
ventional low-energy collimators.
7,8 The most common
semiquantitative parameter is the heart to mediastinal
count ratio (HMR) calculated from the mean count of
the whole heart and upper third of the mediastinum in
planar anterior view. In addition, the washout rate (WR)
was also calculated as the following equation:
Washout ratio of the MIBG
¼ early heart counts   delayed heart counts ðÞ =
early heart counts ðÞ
where each heart counts should be calculated after
background subtraction.
The MIBG HMR as a marker of tracer retention
in the myocardium has been found to be speciﬁc to
sympathetic nerve terminals, whereas the MIBG HR
between the early and the delayed images may rep-
resent a parameter of neurohormonal function. For
assessing regional as well as global neuronal function,
SPECT imaging can be analyzed for regional MIBG
distribution and also defect score may be estimated
as another semiquantitative parameter. A normal
data base recently acquired by multicenter study from
Japan may help precise assessment of SPECT dis-
tribution.
9
MIBG IN HF
HF is a major cause of mortality and represents a
growing health problem.
10,11 While severity of HF is
evaluated mainly from symptoms, clinical ﬁndings,
hemodynamic measurements, left ventricular ejection
fraction (LVEF), or exercise tolerance, the assessment of
neurohormonal system abnormalities related to HF has
proven to be valuable for risk stratiﬁcation.
12-15 Despite
these indices, the accurate evaluation of the cardiovas-
cular risk remains difﬁcult. An increase in presynaptic
activity with a decrease of postsynaptic beta-adrenergic
receptor density is well reported in failing heart.
12,15-19
Because MIBG is an NE analog, WR and delayed
HMR may directly reﬂect NE release from the nerve ter-
minal and its reuptake into the nerve terminal (uptake-1).
In addition, the MIBG WR may reﬂect presynaptic
sympathetic tone. The local NE concentration in the
synaptic cleft increases when WR increases or HMR
decreases.
20-22 MIBG imaging has been widely used for
theassessmentofcardiacsympatheticfunctioninHF
21-26
(Figure 1).
Merlet et al
27 ﬁrst showed the prognostic value of
HMR in patients with HF, although washout kinetics of
MIBG was not assessed in this study. Thereafter many
prognostic studies using this imaging technique have
been performed in European countries and Japan. In
many studies, it has been reported that impaired cardiac
adrenergic innervation as assessed by MIBG imaging
was closely associated with mortality in patients with
HF.
27-36 Tamaki et al
37,38 from Osaka showed the MIBG
value for predicting sudden cardiac death in comparison
with ECG parameters, such as T wave alteration. They
found that MIBG WR was independent of LVEF for
risk analysis in patients with HF. A multivariate Cox
Figure 1. Anterior planar images taken at 4 hour after MIBG administration of a normal subject
(left) and a patient with heart failure (right). A high myocardial uptake is seen in the normal subject,
whereas a severe reduction of MIBG uptake in the myocardium is noted in this patient with heart
failure.
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ECG parameters were signiﬁcant and independent pre-
dictors for sudden cardiac death.
Verberne et al
39 recently reported a meta-analysis of
MIBG imaging in HF. They concluded that decreased
late HMR and increased WR of MIBG indicated a poor
prognosis. Although their conclusion was nearly
consistent with the previous reports, HMR showed sig-
niﬁcant heterogeneity as compared to the consistent
ﬁndings on WR analysis of MIBG for prognostic
assessment. Heterogenic result of HMR may partly be
due to differences in a speciﬁc activity of MIBG, clinical
backgrounds among countries, cumulative death calcu-
lation, and various endpoints used. In addition, a
different gamma camera with collimators with variable
method for in estimation of count density in the myo-
cardium and background activity may possibly cause
heterogenous results in multicenter comparison. In this
respect, standardization of MIBG image acquisitions
and quantitative analysis with their validation should be
established. This standardization is especially important
for multicenter studies.
40
There are some reports indicating MIBG imaging as
a good predictor of response to beta adrenergic blocker
therapy.
41,42 Both studies suggested that relatively pre-
served uptake may represent a good responder, whereas
severely decreased MIBG uptake was associated with a
poor response sign for beta-blocker therapy. Altered
adrenergic presynaptic function may cause postsynaptic
receptor dysfunction. Spyrou et al
43 reported that beta-
adrenergic receptor down-regulation can be used as a
predictor of LV remodeling in patients after acute
myocardial infarction. We recently demonstrated that
myocardial beta-adrenergic receptor down-regulation
estimated by
11CGP-12177 PET may be related with
increased sympathetic tone, shown as increased MIBG
WR.
19 Furthermore, beta-adrenergic receptor down-
regulation may predict improvement of cardiac function
after beta-blocker treatment in patients with dilated
cardiomyopathy.
44 Although this remains preliminary,
adrenergic functional study may contribute to predict
which patients may receive most beneﬁt in patients with
severe HF.
MIBG FOR PREDICTING FATAL ARRHYTHMIAS
Sudden cardiac death due to fatal arrhythmia rep-
resents an important health care problem in many
countries. A number of efforts have been done to
develop suitable therapeutic options, implantable cardi-
overter-deﬁbrillator (ICD) treatment has been well
established for preventive use in patients with high risk
for arrhythmic death.
45,46 Despite clear indication for
ICD treatment, only minority of the patients actually
received this treatment.
47 On the contrary, widespread
use of ICD therapy has increased medical cost and
unfavorable side effects especially for those at lower
risk for sudden cardiac death. While general criteria for
ICD therapy is deﬁned, but has been frequently modiﬁed
since the current criteria remain unsatisfactory.
48-50
Autonomic dysfunction assessed by MIBG is
thought to play an important role in the detection of high
risk ventricular arrhythmia.
51-53 Particularly, MIBG may
identify the areas of denervation hypersensitivity which
may likely to cause ventricular arrhythmias. There are a
number of pilot studies indicated MIBG as a potential
predictor for ventricular arrhythmias in patients with
ICD.
54-56
Jacobson et al
57 report the results of a prospective
MIBG imaging trial of 961 patients with HF recruited at
96 sites in North America and Europe, ADMIRE-HF.
Patients with New York Heart Association (NYHA)
Class II and III HF and LVEF B 35% were enrolled.
They concluded that HMR of\1.6 measured at 4 hours
after MIBG administration provided prognostic data
beyond that available from LVEF, BNP assay, and
NYHA class at the time of enrollment. This important
study indicates adrenergic neuronal functional parameter
obtained by MIBG scan as an important and independent
parameter for predicting sudden death from the com-
monly used LV functional parameters. For patients who
make criteria for ICD but are ambivalent, it provides yet
another means of assessing overall risk of events to
guide clinical decisions.
58
Recently, Boogers et al
59 reported the value of
MIBG imaging in 116 patients with HF who may have a
candidate for ICD treatment. They showed that the
MIBG defect size on delayed SPECT imaging can pre-
dict ventricular arrhythmias causing appropriate ICD
discharge as a primary end point as well as the com-
posite of appropriate ICD therapy or cardiac death as
secondary end point. They also concluded that MIBG
SPECT may improve risk stratiﬁcation for arrhythmic
death in patients who have an indication for ICD treat-
ment. One of the new ﬁndings is that they used different
criteria (denervation as a MIBG defect size) from the
previous reports (mostly HMR as global MIBG uptake
and/or WR). Since MIBG uptake is generally decreased
in many patients with HF, it is often difﬁcult to recon-
struct SPECT images, particularly in those showing
severity decreased MIBG uptake. In addition, it may be
quite unreliable to estimate defects score in such cases
as compared to high myocardial uptake. It would be
better to analyze innervation/perfusion mismatch on
SPECT using two different radiotracers rather than
MIBG SPECT alone. A standardized criteria showing
decreased MIBG uptake or MIBG defect may be
required in the future.
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60 included
prospective study of MIBG imaging in combination with
resting myocardial perfusion imaging in patients who
received ICD treatment. During the mean follow-up of
29 months, ICD shocks (discharge) were documented in
30 of the total of 60 patients (50%). Among various
clinical and scintigraphic variables, both lower HMR on
MIBG and large perfusion defect were the most pow-
erful predictors for ICD discharge on Cox multivariate
analysis. This is the ﬁrst report indicating incremental
beneﬁt in combined assessment of myocardial perfusion
and sympathetic nerve function for appropriate risk
stratiﬁcation of patients who may need prophylactic ICD
therapy. This result indicates both denervation and
myocardial scar were important predictors for ICD dis-
charge and fatal arrhythmias. But it remains unknown
whether a simple perfusion imaging is enough or both
MIBG and perfusion imaging may be required for pre-
diction of such fatal arrhythmias. Another important
issue is whether global assessment using MIBG kinetics
or regional assessment of neuronal function using pre-
cise MIBG SPECT analysis may be required for
prediction of fatal arrhythmias in HF patients. Further
study with larger patients is required to conﬁrm this
preliminary result for cardiologists to use MIBG for
selecting appropriate ICD treatment.
BMIPP IMAGING
15-(p-Iodophenyl)-3R,S-methyl pentadecanoic acid
(BMIPP) is one of iodinated branch-chain fatty acids
introduced by Knapp et al.
61 Because of high uptake and
long retention in the myocardium, BMIPP is particularly
useful for SPECT imaging with a conventional gamma
camera. The unique and desirable properties of methyl-
branched fatty acids are due to the inhibition of beta-
oxidation by the presence of a methyl group in the
beta-position.
Animal experiments have demonstrated that the
clearance of BMIPP from the myocardium is slow with
approximately 25% clearance in 2 hours.
61 The frac-
tional distribution of these compounds at 30 minutes
after tracer injection in rats showed that 65-80% of the
total activity resided in the triglyceride pool.
BMIPP was usually injected under fasting condition
and SPECT imaging was obtained about 15-30 minutes
after intravenous administration of 111-148 MBq
(3-4 mCi) of BMIPP. BMIPP has been most widely used
over 10 years in Japan.
62-64
In general, BMIPP uptake was similar to regional
perfusion seen on thallium-201 or technetium-99m
perfusion agents. In the areas with perfusion abnormal-
ities, BMIPP uptake is also decreased. But the
discrepancy of perfusion and metabolism is often
observed under various circumstances, including myo-
cardial ischemia.
56-58 In order to identify the perfusion-
metabolism mismatch, regional BMIPP uptake is often
compared with regional perfusion.
BMIPP FOR IDENTIFYING ISCHEMIA
Ischemia may cause reduction of fatty acid utiliza-
tion and shift from fatty acid to glucose utilization. In
addition, such metabolic shift may persist shortly after
recovery of ischemia. Thus, BMIPP uptake is often seen
in ischemic myocardium, mainly due to persistent sup-
pression of fatty acid metabolism after severe ischemia.
This metabolic alteration as a result of prior ischemia is
so called as ischemic memory (Figure 2).
63-65 Such
ischemic memory imaging may be used with BMIPP,
since reduction of BMIPP uptake may identify prior
ischemic insult after recovery of perfusion. A number of
reports have indicated that BMIPP imaging at rest
can be used for identifying ischemic myocardium in
coronary patients without evidence of myocardial
infarction
66-73 (Figure 2). Recent meta-analysis from
MEDLINE search of the published literature conﬁrmed
that BMIPP SPECT at rest exhibited a moderate sensi-
tivity and high speciﬁcity to detect CAD lesions with a
high prevalence of CAD.
74 They concluded BMIPP may
be of great value for patients with acute chest pain and
those with relatively contraindications to exercise or
pharmacologic stress myocardial perfusion imaging.
The important point is that all these results were
obtained with BMIPP imaging at rest, not under stress
imaging to identify myocardial ischemia. When the
BMIPP imaging was compared with stress myocardial
perfusion imaging for the same patients suspected with
CAD, the diagnostic accuracy was similar or slightly
less than those of stress myocardial perfusion imaging.
75
BMIPP abnormalities tended to be associated with
unstable angina, regional wall motion abnormalities, and
ECG changes, reﬂecting severe ischemia.
69,75
One of the major applications of BMIPP is to
accurate diagnosis of acute coronary syndrome in
emergency unit. We applied both BMIPP and myocar-
dial perfusion imaging performed at rest for 111
consecutive patients with acute chest pain.
72 All of them
received coronary angiography to conﬁrm the radionu-
clide ﬁndings. BMIPP imaging acquired within 48 hours
after the last chest pain showed sensitivity of 74% and
speciﬁcity of 92% doe identifying coronary stenosis,
which was better than the resting myocardial perfusion
imaging taken within 24 hours after the chest pain. This
is the ﬁrst report showing the value of BMIPP for
identifying prior ischemic insult after recovery of chest
pain in emergency department. In addition, altered
BMIPP uptake was seen in many patients having
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ﬁrmed by multicenter study in United States.
76,77 They
concluded that BMIPP SPECT in emergency department
had similar sensitivity for detection patients with acute
coronary syndrome with other contemporary imaging
modalities. But BMIPP has a unique property of main-
taining sensitivity even when performed up to 30 hours
after symptom resolution.
Since less BMIPP uptake than perfusion may rep-
resent ischemic and jeopardized myocardium, the
combined imaging with BMIPP and perfusion imaging
may hold a prognostic value for identifying high-risk
subgroups among patients with CAD.
78-81 Such prog-
nostic studies have been extended to angina patients
without prior myocardial infarction.
82,83 When 167
consecutive patients with angina were followed-up for
48 months, BMIPP defect score at rest, stress perfusion
score, diabetes, and LVEF were independent predictors
on the multivariate Cox’s analysis.
82 No hard event was
observed with normal BMIPP uptake, whereas two
patients with nearly normal stress perfusion with
abnormal BMIPP uptake had hard cardiac events. These
preliminary reports may indicate a decrease in BMIPP
uptake as an important prognostic indicator independent
of stress induced ischemia on myocardial perfusion
imaging in patients with angina without prior myocar-
dial infarction. A recent systemic review of current
literature suggested that an abnormal ﬁnding on BMIPP
imaging was signiﬁcantly associated with future
cardiovascular outcomes across the spectrum of CAD.
84
Thus, BMIPP imaging at rest may be useful for risk
stratiﬁcation of patients with CAD, particularly those
with acute chest pain. A large prospective randomized
control trial is warranted to conﬁrm the prognostic value
of BMIPP imaging for CAD patients.
BMIPP IN CKD
CAD is often accompanied with CKD. Of particu-
lar, CAD may be the main cause of deaths in patients
with end-stage renal disease (ESRD) who undergo renal
replacement therapy. The incidence of cardiac death is
higher among patients on hemodialysis when compared
with the general population. This is probably due to the
high prevalence of either underlying obstructive CAD or
cardiovascular risk factors in those with ESRD.
85-87
Insulin resistance is a common feature of patients with
ESRD,
88 it is linked with vascular endothelial dysfunc-
tion and it plays an important role in the clustering of
risk factors of atherosclerosis.
89-91 In addition, endo-
thelial damage caused by insulin resistance appears to
have particularly signiﬁcant effects on small arteri-
oles.
92-94 Use of contrast materials may not be suitable
for those patients, and therefore, CT angiography or
coronary angiography is not applied for screening CAD.
While stress perfusion imaging is a method of choice to
rule out CAD, stress test may not be suitable for many of
these patients.
Figure 2. A A series of short axis slices of resting perfusion (top), pharmacological stress
perfusion (middle), and resting BMIPP (bottom) in a 55-year-old patient with coronary artery
disease. While mild stress-induced ischemia is seen in inferior regions, a greater decrease in BMIPP
uptake at rest is noted in inferior and lateral regions. B Right coronary arteriogram of the same
patient shows a severe stenosis on proximal portion of the right coronary artery (arrow).
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means for identifying ischemia and/or ischemic history
of ischemia (ischemic memory) as an area of reduced
BMIPP uptake at rest. Based on these results, Nishimura
et al
95 ﬁrst applied BMIPP imaging for detection of
CAD in hemodialysis patients. They demonstrated high
prevalence of BMIPP abnormalities and coronary arte-
riography conﬁrmed coronary stenosis on those showing
BMIPP abnormalities. These patients often have silent
myocardial ischemia but many of these patients may not
be feasible to receive stress perfusion imaging. In this
respect, BMIPP imaging may hold a promise to identify
ischemia at rest without stress study. Based on the idea
that BMIPP abnormalities are associated with severe
ischemia and jeopardized myocardium, we hypothesized
that those with severe BMIPP abnormalities may have
poor outcome on the follow-up in hemodialysis patients.
In the prospective 375 asymptomatic hemodialysis
patients, severe BMIPP defect identify high-risk for
cardiac death on the follow-up study.
96 In addition,
BMIPP and perfusion mismatch also showed a signiﬁ-
cant predictor for cardiac death in these patients.
Furthermore, BMIPP ﬁndings may also be associated
cardiac death after coronary revascularization in these
patients.
97 These data indicate that many hemodialysis
patients may have silent myocardial ischemia and
infarction. Since severe metabolic alteration may have
future fatal events, BMIPP may have an important role
to select such high risk group who may require early
revascularization therapy.
Based on this experience, a multicenter prospective
trial has recently been designed to investigate the
applicability of BMIPP-SPECT imaging for detection of
CAD and prediction of cardiac events in hemodialysis
patients. We call this study as BMIPP-SPECT analysis
for decreasing cardiac events (B-SAFE in hemodialysis
patients).
98 Regional decrease in BMIPP uptake in the
left ventricular myocardium was occasionally observed
similarly to the previous reports in these patients with
hemodialysis. The frequency of the BMIPP abnormali-
ties and their relation to the various clinical data has
been precisely investigated at present. In addition,
prognostic study will come out in a moment. This is the
ﬁrst multicenter cohort study to demonstrate frequency
of BMIPP abnormalities in relation to various clinical
parameters and to clarify the value of new fatty acid
imaging to detect CAD and assess risk stratiﬁcation in
patients with hemodialysis. On the other hand, there has
been no deﬁnite study showing the value of BMIPP
imaging for general population of CKD without he-
modialysis. Many CKD patients may often have silent
ischemia. Particularly, the CKD patients with high risk
subgroup are good candidate for stress myocardial per-
fusion imaging to rule out CAD. But some patients may
not be suitable for exercise or pharmacological stress
test. In this respect, BMIPP imaging may be one of
alternative for CAD diagnosis and further management
without need of stress condition.
CONCLUSIONS
Both MIBG and BMIPP imaging has provided
valuable for assessment of myocardial disorders in
various clinical settings. MIBG has been used for
assessing severity of HF and prognosis. In addition, it
has a potential role to predict fatal arrhythmia, partic-
ularly for those who had and are planned to receive
implantable ICD treatment. In this sense, MIBG may
hold a promise for reducing medical cost and proving
personalized medicine in patients with severe HF.
BMIPP plays an important role for identifying ischemia
at rest, based on the unique capability to represent
persistent metabolic alteration after recovery of ische-
mia, so called ischemic memory. Since BMIPP
abnormalities may represent severe ischemia or jeop-
ardized myocardium, it may permit risk analysis in
CAD patients, particularly for those with CKD and/or
hemodialysis patients. Such iodinated imaging provides
unique molecular and cellular functions beyond myo-
cardial perfusion and cardiac function in vivo. Such
imaging may hold a promise to play an important role
to select which individual patient may require expen-
sive new treatment, and thus, to permits suitable
treatment strategy in cardiovascular diseases in the near
future.
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